Business
Lenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care Settings
Findings reinforce Nuwellis’ leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload.MINNEAPOLIS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay between the heart and kidneys, today announced the presentation of new real-world data from New York City’s Lenox Hill Hospital at the 2025 American Society
About this update from Nuwellis, Inc.
[{"type":"image","alt":"Nuwellis, Inc.","displaySize":"","headline":null,"caption":"Nuwellis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/epm_zxode7LAVlWVBg62FQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b","width":300,"height":72}},"lazy":false},{"type":"text","content":"Findings reinforce Nuwellis’ leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload.","length":126,"tagName":"p"},{"type":"text","content":"MINNEAPOLIS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay between the heart and kidneys, today announced the presentation of new real-world data from New York City’s Lenox Hill Hospital at the 2025 American Society of Nephrology (ASN) Kidney Week, reinforcing the versatility of Aquadex® ultrafiltration therapy in patients with acute kidney injury (AKI) and complex fluid management needs.","length":549,"tagName":"p"},{"type":"text","content":"The retrospective analysis, titled “Diversifying Aquapheresis Applications in Critical Care: Nephrology-Led Institutional Experience” (Presentation #FR-PO0590), reviewed 69 cases treated with Aquadex between 2018 and 2024. The study demonstrated effective and predictable fluid removal in patients with multiple underlying conditions—ranging from oliguric AKI and post-cardiac-surgery volume overload to pre-operative optimization in end-stage renal disease.","length":458,"tagName":"p"},{"type":"text","content":"The analysis found that patients had an average of 6.4 liters of ultrafiltrate removed over a mean duration of 78 hours, with stable hemodynamics even among those on vasopressor support.","length":186,"tagName":"p"},{"type":"text","content":"“Volume optimization remains a cornerstone of critical-care management,” said Eduardo Pino Domenech, MD, Nephrologist at Lenox Hill Hospital and lead author of the study. “Our experience shows that Aquadex can be safely applied across a wide range of complex patients, offering clinicians an additional tool t...